2003年9月
Inhibition of induction of myofibroblasts by interferon gamma in a human fibroblast cell line
INTERNATIONAL IMMUNOPHARMACOLOGY
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 3
- 号
- 9
- 開始ページ
- 1273
- 終了ページ
- 1280
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1016/S1567-5769(03)00102-4
- 出版者・発行元
- ELSEVIER SCIENCE BV
Interferon gamma (IFNgamma) has been reported as a possible therapeutic agent for contractile diseases in clinical trials and in vitro studies. It is not yet clear, however, whether IFNgamma simply inhibits myofibroblast generation or downregulates alpha smooth muscle actin (alphaSMA) production in myofibroblasts. In this study, we attempted to clarify how IFNgamma acts in the generation of myofibroblasts, and the production of alphaSMA by myofibroblasts, using immunofluorescence staining, cell capture enzyme immunoassay (CC-EIA) and the reverse transcription polymerase chain reaction (RT-PCR) for alphaSMA.
We examined whether IFNgamma could block the TGFbeta1-promoted changes in myofibroblasts or the generation of myofibroblasts by TGFbeta1. IFNgamma strongly blocked the generation of myofibroblasts and moderately inhibited the production of alphaSMA in TGFbeta1-promoted myofibroblasts. These findings indicate that IFNgamma may be effective in the early stage of contractile diseases to prevent the progression of contractile lesions. (C) 2003 Elsevier B.V. All rights reserved.
We examined whether IFNgamma could block the TGFbeta1-promoted changes in myofibroblasts or the generation of myofibroblasts by TGFbeta1. IFNgamma strongly blocked the generation of myofibroblasts and moderately inhibited the production of alphaSMA in TGFbeta1-promoted myofibroblasts. These findings indicate that IFNgamma may be effective in the early stage of contractile diseases to prevent the progression of contractile lesions. (C) 2003 Elsevier B.V. All rights reserved.
- リンク情報
- ID情報
-
- DOI : 10.1016/S1567-5769(03)00102-4
- ISSN : 1567-5769
- Web of Science ID : WOS:000185154100004